Samsung BioLogics IPO Could Value Firm at $8.2 Billion

Samsung Group ’s biologic drug manufacturing arm announced fresh details on its plans for a November listing, the same day its subsidiary said it had sought European approval for a near-replica of top-selling cancer drug Herceptin.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news